MX337100B - Compuestos alcoxi para el tratamiento de enfermedades. - Google Patents

Compuestos alcoxi para el tratamiento de enfermedades.

Info

Publication number
MX337100B
MX337100B MX2012010794A MX2012010794A MX337100B MX 337100 B MX337100 B MX 337100B MX 2012010794 A MX2012010794 A MX 2012010794A MX 2012010794 A MX2012010794 A MX 2012010794A MX 337100 B MX337100 B MX 337100B
Authority
MX
Mexico
Prior art keywords
disorders
disease treatment
alkoxy compounds
compositions
compounds
Prior art date
Application number
MX2012010794A
Other languages
English (en)
Inventor
Mark W Orme
Vladimir A Kuksa
Thomas Little
Anna Gall
Feng Hong
Ian L Scott
Original Assignee
Acucela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acucela Inc filed Critical Acucela Inc
Publication of MX337100B publication Critical patent/MX337100B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/20—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/72—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/06—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/33—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Abstract

La presente invención se refiere en general a composiciones y métodos para tratar enfermedades y trastornos neurodegenerativos, en particular enfermedades y trastornos oftálmicos. Se proveen en la presente compuestos derivados de alcoxilo y composiciones farmacéuticas que comprenden estos compuestos. Las composiciones objeto son de utilidad para el tratamiento y la prevención de enfermedades oftálmicas y trastornos, incluyendo degeneración macular relacionada con la edad (AMD) y enfermedad de Stargardt.
MX2012010794A 2007-10-05 2008-10-03 Compuestos alcoxi para el tratamiento de enfermedades. MX337100B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US97795707P 2007-10-05 2007-10-05
US6635308P 2008-02-19 2008-02-19
US4312708P 2008-04-07 2008-04-07
US5165708P 2008-05-08 2008-05-08
US6008308P 2008-06-09 2008-06-09
PCT/US2008/011421 WO2009045479A1 (en) 2007-10-05 2008-10-03 Alkoxy compounds for disease treatment

Publications (1)

Publication Number Publication Date
MX337100B true MX337100B (es) 2016-02-11

Family

ID=40042269

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2010003667A MX2010003667A (es) 2007-10-05 2008-10-03 Compuestos alcoxi para el tratamiento de enfermedades.
MX2012010794A MX337100B (es) 2007-10-05 2008-10-03 Compuestos alcoxi para el tratamiento de enfermedades.
MX2015017571A MX354184B (es) 2007-10-05 2008-10-03 Compuestos alcoxi para el tratamiento de enfermedades.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010003667A MX2010003667A (es) 2007-10-05 2008-10-03 Compuestos alcoxi para el tratamiento de enfermedades.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015017571A MX354184B (es) 2007-10-05 2008-10-03 Compuestos alcoxi para el tratamiento de enfermedades.

Country Status (20)

Country Link
US (12) US7982071B2 (es)
EP (2) EP2091955B1 (es)
JP (3) JP5913805B2 (es)
KR (1) KR101224798B1 (es)
CN (2) CN103553945B (es)
AR (1) AR071050A1 (es)
AU (1) AU2008307492B2 (es)
CA (1) CA2701116C (es)
CO (1) CO6270259A2 (es)
ES (2) ES2772949T3 (es)
GB (1) GB2454555B (es)
HK (2) HK1129328A1 (es)
MX (3) MX2010003667A (es)
MY (2) MY155320A (es)
NZ (1) NZ584599A (es)
RU (2) RU2014151622A (es)
SG (1) SG185276A1 (es)
TW (1) TW200922548A (es)
UA (1) UA110089C2 (es)
WO (1) WO2009045479A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5042215B2 (ja) 2005-05-26 2012-10-03 ニューロン システムズ， インコーポレイテッド 網膜疾患を処置するための組成物および方法
MY155320A (en) 2007-10-05 2015-09-30 Acucela Inc Alkoxy compounds for disease treatment
KR101111710B1 (ko) * 2008-01-29 2012-03-13 히다치 막셀 가부시키가이샤 절연층 형성용 슬러리, 전기화학소자용 세퍼레이터 및 그 제조방법, 및 전기화학소자
US20120150029A1 (en) * 2008-12-19 2012-06-14 University Of Miami System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography
WO2010080576A1 (en) 2008-12-19 2010-07-15 University Of Miami System and method for early detection of diabetic retinopathy using optical coherence tomography
EP4000610A1 (en) * 2009-07-02 2022-05-25 Acucela Inc. Pharmacology of visual cycle modulators
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
MX2012007759A (es) 2009-12-29 2012-08-01 Mapi Pharma Ltd Compuestos intermedios y procesos para la preparacion de tapentadol y compuestos relacionados.
KR20140097127A (ko) 2011-09-16 2014-08-06 포비어 파마수티칼스 아닐린 유도체, 그의 제조법 및 그의 치료 용도
EP2804605A4 (en) * 2012-01-20 2015-07-08 Acucela Inc SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
TW201406707A (zh) * 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
RU2015120478A (ru) 2012-12-20 2017-01-25 Альдейра Терапьютикс, Инк. Пери-карбинолы
KR102243169B1 (ko) 2013-01-23 2021-04-22 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
CN105228989A (zh) 2013-01-25 2016-01-06 奥尔德拉医疗公司 黄斑变性治疗中的新颖捕获剂
BR112015022041A2 (pt) * 2013-03-12 2017-07-18 Acucela Inc derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
WO2014200094A1 (ja) 2013-06-14 2014-12-18 日産化学工業株式会社 光学活性アルコール化合物の製造方法
US11040937B2 (en) 2014-02-28 2021-06-22 Tohoku University Amide derivative
EP3337486B1 (en) 2015-08-21 2024-04-03 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CA3016759A1 (en) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
KR101935636B1 (ko) * 2016-11-04 2019-01-07 에스티팜 주식회사 (s)-n1-(2-아미노에틸)-3-(4-알콕시페닐)프로판-1,2-디아민 3염산염의 제조방법
US11253489B2 (en) 2017-02-27 2022-02-22 Case Western Reserve University Visual cycle modulators
WO2018170476A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN107089920A (zh) * 2017-04-25 2017-08-25 武汉理工大学 L‑3‑n，n‑二苄基氨基‑1‑（3‑环己基甲氧基）苯基）丙‑1‑醇的制备方法
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
EP3694500A4 (en) 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
IL277812B2 (en) * 2018-04-10 2023-10-01 Bayer Ag Process for the production of 6,2-dialkylphenyl acetic acids
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
CN115869258A (zh) 2018-09-25 2023-03-31 奥尔德拉医疗公司 用于治疗干眼病的调配物
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2021064695A1 (en) 2019-10-04 2021-04-08 Novartis Ag Methods for measuring cralbp activity
CN114874417B (zh) * 2022-04-29 2023-05-26 万华化学集团股份有限公司 一种环氧树脂稀释剂及其制备方法与应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH396941A (de) * 1959-08-10 1965-08-15 Ciba Geigy Verfahren zur Herstellung neuer sekundärer Amine
GB884663A (en) * 1958-11-06 1961-12-13 Ciba Ltd New amines and processes for their manufacture
CH380746A (de) * 1958-11-06 1964-08-15 Ciba Geigy Verfahren zur Herstellung neuer sekundärer Amine
CH433246A (de) * 1962-06-25 1967-04-15 Ciba Geigy Verfahren zur Herstellung von Guanidinverbindungen
GB1145278A (en) * 1964-07-07 1969-03-12 Wellcome Found Amidine derivatives, processes for their preparation, and compositions incorporating them
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
JPS50112386A (es) * 1974-02-27 1975-09-03
DE2710997C3 (de) * 1977-03-14 1980-08-14 Dr. Karl Thomae Gmbh, 7950 Biberach 4-Alkoxy carbonylamino-phenyläthanolamine, deren Herstellung und deren Verwendung als Arzneimittel
US4569354A (en) 1982-03-22 1986-02-11 Boston University Method and apparatus for measuring natural retinal fluorescence
JPS6025958A (ja) * 1983-07-21 1985-02-08 Kowa Co 新規アミノアルキル置換ベンゼン誘導体
JPH0228112A (ja) * 1988-04-21 1990-01-30 Kaken Pharmaceut Co Ltd 点眼用眼圧調整剤
US5135955A (en) * 1988-04-25 1992-08-04 Eli Lilly And Company Propanamine derivatives
IT1240427B (it) * 1990-03-02 1993-12-15 Ministero Dall Uni E Della Ric Arilpropilammine ad azione antifungina
DE4035961A1 (de) 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69224861T2 (de) 1991-07-30 1998-08-06 Korea Res Inst Chem Tech Neue Phenylacetamidderivate und Verfahren zu ihrer Herstellung
WO1993015045A1 (en) * 1992-01-29 1993-08-05 Smithkline Beecham Corporation N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives
JPH09507672A (ja) * 1994-01-19 1997-08-05 ビイク ネダーラント ベスローテン フェンノートシャップ ニトロキシ基含有ベンジルアミン誘導体及び循環器疾患並びに眼内圧増加の治療のためのその使用
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
JP2007008957A (ja) 1994-08-22 2007-01-18 Mitsubishi Pharma Corp ベンゼン化合物およびその医薬としての用途
US5541228A (en) 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
CA2159759A1 (en) * 1994-10-14 1996-04-15 Katherine S. Takaki Melatonergic agents
IL117580A0 (en) * 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5631280A (en) * 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
FR2747690B1 (fr) 1996-04-19 1998-06-12 Neurotech Sa Lignees immortalisees de cellules retiniennes et leurs applications au traitement de differents troubles primaires ou secondaires ophtalmologiques ou neurologiques
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US6090624A (en) 1996-04-19 2000-07-18 Brown University Research Foundation Immortalized retinal cell lines and their applications
US5654431A (en) 1996-05-30 1997-08-05 Meng; Qingchang 5-alkoxy tryptamine derivatives
WO1997046511A1 (en) 1996-06-07 1997-12-11 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AUPO235996A0 (en) 1996-09-16 1996-10-10 Garvan Institute Of Medical Research Method of cell culture
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
AU736481C (en) * 1996-10-07 2002-06-06 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation
DE19643592A1 (de) * 1996-10-22 1998-04-23 Bayer Ag Verfahren zur Herstellung von alpha-Alkoxy-alpha-trifluormethyl-arylessigsäureestern und -arylessigsäuren
US6713300B1 (en) 1997-02-27 2004-03-30 University Of Utah Research Foundation Nucleic acid and amino acid sequences for ATP-binding cassette transporter and methods of screening for agents that modify ATP-binding cassette transporter
TW593331B (en) * 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6051605A (en) * 1997-08-08 2000-04-18 Warner-Lambert Company Method of treating psychosis and schizophrenia
US6271385B1 (en) 1997-09-11 2001-08-07 Kureha Kagaku Kogyo Kabushiki Kaisha N-heterocyclic methylpropylamine derivatives, process for producing the same and germicides
US6171837B1 (en) 1997-09-29 2001-01-09 The Trustees Of Columbia University In The City Of New York Mouse and human 9-cis-retinol dehydrogenase
AU1996599A (en) 1997-12-05 1999-06-28 Board Of Trustees Of The Leland Stanford Junior University Long-term survival and regeneration of central nervous system neurons
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
IL143382A0 (en) 1999-01-05 2002-04-21 Aventis Pharma Sa Human adult astrocytes, their preparation and uses thereof
JP2001031636A (ja) 1999-05-18 2001-02-06 Senju Pharmaceut Co Ltd α−ケトアミド誘導体およびその医薬用途
AU6391000A (en) 1999-07-28 2001-02-19 Genentech Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
EP1107003A1 (en) 1999-12-09 2001-06-13 Trophos Methods for screening compounds active on neurons
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
AU1464101A (en) * 1999-12-21 2001-07-03 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
WO2001083714A2 (en) 2000-05-02 2001-11-08 Central Institute For The Deaf Composition and methods for treating photoreceptor degeneration
JP2003342261A (ja) 2000-05-09 2003-12-03 Kureha Chem Ind Co Ltd Ｎ−ヘテロ環メチル−アルキルアミン誘導体、その製造方法、および殺菌剤
US20020009713A1 (en) 2000-05-11 2002-01-24 Miller Freda D. Methods for identifying modulators of neuronal growth
EP1292601A2 (en) 2000-05-30 2003-03-19 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating retinal disorders and glaucoma
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
DE10141018A1 (de) 2001-08-22 2003-03-13 Eth Zuerich Eidgenoessische Te Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003249227A1 (en) 2002-07-12 2004-02-02 University Of Washington Methods and systems for extended in vitro culture of neuronal cells
DE10235312A1 (de) * 2002-08-01 2004-02-12 Basf Ag Verfahren zur Herstellung von Aminoalkoxybenzylaminen und Aminoalkoxybenzonitrilen als Zwischenprodukte
CA2505608A1 (en) 2002-12-06 2004-06-24 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
EP2324823A3 (en) 2003-03-14 2011-11-16 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
JP2007500509A (ja) 2003-07-30 2007-01-18 アクセラ， インコーポレイテッド 長期一次網膜細胞培養およびストレスモデル、ならびにこれらの使用方法
CN101407471A (zh) * 2003-08-29 2009-04-15 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
MXPA06002310A (es) * 2003-08-29 2006-05-25 Ono Pharmaceutical Co Compuesto capaz de enlazarse al receptor s1p y uso farmaceutico del mismo.
US7706863B2 (en) 2004-01-21 2010-04-27 University Of Washington Methods for assessing a physiological state of a mammalian retina
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
US20050260180A1 (en) * 2004-03-12 2005-11-24 Genvec, Inc. Materials and methods for treating vascular leakage in the eye
JP2007529434A (ja) 2004-03-17 2007-10-25 ラース マイケル ラーセン， 視覚サイクルの阻害による網膜症の予防
US20060252107A1 (en) 2005-02-22 2006-11-09 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
WO2006105215A2 (en) 2005-03-28 2006-10-05 Acucela, Inc. The use of a spin trap for enhancing retinal cell survival and treating retinal degenerative diseases
PE20061378A1 (es) * 2005-04-20 2006-12-03 Smithkline Beecham Corp INHIBIDORES DE LA ACTIVIDAD DE Akt
US8098907B2 (en) 2005-07-01 2012-01-17 Siemens Corporation Method and system for local adaptive detection of microaneurysms in digital fundus images
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
EP1973868B1 (en) * 2006-01-13 2015-09-09 McGill University Novel elatonin ligands having antidepressant activity as well as sleep inducing properties
WO2007100777A2 (en) * 2006-02-28 2007-09-07 The Mclean Hospital Corporation Methods for the treatment of adhd and related disorders
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
MY155320A (en) 2007-10-05 2015-09-30 Acucela Inc Alkoxy compounds for disease treatment
EP4000610A1 (en) 2009-07-02 2022-05-25 Acucela Inc. Pharmacology of visual cycle modulators
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
JP6502742B2 (ja) 2015-05-11 2019-04-17 川崎重工業株式会社 建設機械の油圧駆動システム

Also Published As

Publication number Publication date
US9737496B2 (en) 2017-08-22
AU2008307492B2 (en) 2013-03-14
CA2701116A1 (en) 2009-04-09
HK1129328A1 (en) 2009-11-27
GB0818175D0 (en) 2008-11-12
JP5898758B2 (ja) 2016-04-06
US20230218549A1 (en) 2023-07-13
JP2011512321A (ja) 2011-04-21
EP2091955A4 (en) 2013-01-02
RU2541430C2 (ru) 2015-02-10
KR20100066577A (ko) 2010-06-17
US8981153B2 (en) 2015-03-17
US7982071B2 (en) 2011-07-19
US11446261B2 (en) 2022-09-20
EP3210966A1 (en) 2017-08-30
MX354184B (es) 2018-02-16
US20120129894A1 (en) 2012-05-24
CN103553945A (zh) 2014-02-05
UA110089C2 (uk) 2015-11-25
KR101224798B1 (ko) 2013-01-21
AR071050A1 (es) 2010-05-26
NZ584599A (en) 2012-07-27
US20130197096A1 (en) 2013-08-01
US10639286B2 (en) 2020-05-05
US8993807B2 (en) 2015-03-31
ES2615389T3 (es) 2017-06-06
US20190183816A1 (en) 2019-06-20
EP2091955A1 (en) 2009-08-26
US20170049722A1 (en) 2017-02-23
CN101889017A (zh) 2010-11-17
JP2015091831A (ja) 2015-05-14
MY160052A (en) 2017-02-15
JP2014196287A (ja) 2014-10-16
JP5913805B2 (ja) 2016-04-27
RU2014151622A (ru) 2015-08-20
US9079825B2 (en) 2015-07-14
GB2454555B (en) 2011-01-26
US20180177746A1 (en) 2018-06-28
MX2010003667A (es) 2010-09-28
TW200922548A (en) 2009-06-01
EP2091955B1 (en) 2016-12-07
US20150239825A1 (en) 2015-08-27
US20120122938A1 (en) 2012-05-17
US9458088B2 (en) 2016-10-04
US8829244B2 (en) 2014-09-09
US20210077427A1 (en) 2021-03-18
AU2008307492A1 (en) 2009-04-09
HK1192219A1 (en) 2014-08-15
RU2010117740A (ru) 2011-11-10
US20150239836A1 (en) 2015-08-27
US10188615B2 (en) 2019-01-29
WO2009045479A1 (en) 2009-04-09
GB2454555A (en) 2009-05-13
CN101889017B (zh) 2013-11-27
ES2772949T3 (es) 2020-07-08
CA2701116C (en) 2013-02-05
MY155320A (en) 2015-09-30
SG185276A1 (en) 2012-11-29
CN103553945B (zh) 2015-01-07
CO6270259A2 (es) 2011-04-20
US20090326074A1 (en) 2009-12-31
EP3210966B1 (en) 2020-01-08
US20120214852A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
MX354184B (es) Compuestos alcoxi para el tratamiento de enfermedades.
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
MX2010000351A (es) Compuestos derivados de alquinil fenilo para tratar enfermedades y desordenes oftalmicos.
MX2009011360A (es) Compuestos derivados de estirenilo para tratar enfermedades y trastornos oftalmicos.
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
EA025086B9 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.
WO2010066684A3 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
HK1113797A1 (en) Quinoline derivative for the treatment of retinal diseases
MX2007008848A (es) Metodos y composiciones para el tratamiento de desordenes oculares.
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
TW200628473A (en) Novel heterocycles
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
TW200732304A (en) Piperidine derivatives
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
TW200740825A (en) Cripowellins and synthetic derivatives thereof as medicaments
WO2007022938A3 (en) Compounds
TW200738640A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MX2019008130A (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.